These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29376753)

  • 1. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.
    Totzeck M; Mincu RI; Mrotzek S; Schadendorf D; Rassaf T
    Eur J Prev Cardiol; 2018 Mar; 25(5):482-494. PubMed ID: 29376753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
    Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
    Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
    Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
    [No Abstract]   [Full Text] [Related]  

  • 6. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
    Chen YC; Chen JH; Hsieh FI
    J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
    Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
    Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Schutz FA; Je Y; Richards CJ; Choueiri TK
    J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
    Li J; Gu J
    Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
    Sivendran S; Liu Z; Portas LJ; Yu M; Hahn N; Sonpavde G; Oh WK; Galsky MD
    Cancer Treat Rev; 2012 Nov; 38(7):919-25. PubMed ID: 22651902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
    Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
    Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
    Totzeck M; Mincu RI; Rassaf T
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
    Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
    Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.
    Qi WX; Shen Z; Tang LN; Yao Y
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):71-82. PubMed ID: 24878433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Choueiri TK; Rocha P; Naik G; Sonpavde G
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):136-45. PubMed ID: 25541349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.